首页 > 最新文献

Infectious Diseases: News, Opinions, Training最新文献

英文 中文
Prophylactic measures efficiency evaluation in preventing tick-borne encephalitis infection 预防蜱传脑炎感染的预防措施效果评价
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-1-40-46
N. Poltoratskaya, T. N. Poltoratskaya, N. Zhukova, E. Adaev, A. Shikhin, T. Pankina, K.N. Sunchugasheva
{"title":"Prophylactic measures efficiency evaluation in preventing tick-borne encephalitis infection","authors":"N. Poltoratskaya, T. N. Poltoratskaya, N. Zhukova, E. Adaev, A. Shikhin, T. Pankina, K.N. Sunchugasheva","doi":"10.33029/2305-3496-2023-12-1-40-46","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-1-40-46","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety assessment of the use of thioureidoiminomethylpyridinium perchlorate (Perchlozone) in the treatment of drug-resistant tuberculosis in patients with HIV infection 高氯酸硫脲亚胺甲基吡啶治疗HIV感染患者耐药结核的安全性评价
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-1-69-74
E. Shuvalova, A. Panteleev, A. Daynovets, E.N. Udaltsova
{"title":"Safety assessment of the use of thioureidoiminomethylpyridinium perchlorate (Perchlozone) in the treatment of drug-resistant tuberculosis in patients with HIV infection","authors":"E. Shuvalova, A. Panteleev, A. Daynovets, E.N. Udaltsova","doi":"10.33029/2305-3496-2023-12-1-69-74","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-1-69-74","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermediate hosts of multilocularis hydatyd disease 多房水螅病的中间宿主
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-2-29-33
O. Andreyanov
{"title":"Intermediate hosts of multilocularis hydatyd disease","authors":"O. Andreyanov","doi":"10.33029/2305-3496-2023-12-2-29-33","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-2-29-33","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized approach to the management of a patient with COVID-19 with a complicated comorbid background 具有复杂合并症背景的COVID-19患者的个性化治疗方法
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-1-116-122
S. Chepurnenko, G. Shavkuta, N. M. Bulgakova, A. V. Safonova
The aim of the work is to form the principles of a personalized approach to the management of patients with COVID-19 with a complicated comorbid background. Material and methods. The article describes a clinical case of successful recovery of an 87-year-old patient from a new coronavirus infection COVID-19, complicated by pneumonia involving 36% of the lung parenchyma area. Along with age, the situation was aggravated by the comorbid status of the patient: the presence of chronic lymphocytic leukemia, hypertension, mechanical prostheses of the mitral and aortic valves, postinfarction cardiosclerosis, paroxysmal atrial fibrillation, type 2 diabetes mellitus, stage 4 CKD, anemic syndrome, and subclinical hypothyroidism. Results. The C-reactive protein level at admission was 114.46 mg/L. The patient refused hospitalization. Baricitinib 4 mg, favipiravir according to the scheme, vitamin D 2000 units were prescribed for the previously taken therapy. Already after 3 days, C-reactive protein decreased by 4.6 times, and by the 8th day by 15.5 times and amounted to 7.38 mg/ml. The temperature returned to normal on day 2 from the start of baricitinib. In dynamics, a decrease in creatinine level to 177.0 mumol/l was noted, the glomerular filtration rate increased to 30 ml/min/1.73 m2, which corresponded to stage 3b of CKD (a pronounced decrease in glomerular filtration rate). Conclusion. Despite the age of the patient, many comorbidities, each of which could be fatal, the timely use of baricitinib on an outpatient basis made it possible to stop the progressive course of the disease.Copyright © Eco-Vector, 2023. All rights reserved.
这项工作的目的是形成具有复杂合并症背景的COVID-19患者个性化管理方法的原则。材料和方法。本文描述了一名87岁的新型冠状病毒感染COVID-19患者成功康复的临床病例,并合并肺实质面积36%的肺炎。随着年龄的增长,患者的合并症加重了这种情况:慢性淋巴细胞白血病、高血压、二尖瓣和主动脉瓣机械假体、梗死后心脏硬化、阵发性心房颤动、2型糖尿病、4期CKD、贫血综合征和亚临床甲状腺功能减退。结果。入院时c反应蛋白水平为114.46 mg/L。病人拒绝住院治疗。Baricitinib 4mg, favipiravir根据方案,维生素D 2000单位为先前采取的治疗处方。3天后,c反应蛋白下降了4.6倍,到第8天下降了15.5倍,达到7.38 mg/ml。开始使用巴西替尼后第2天体温恢复正常。在动力学上,肌酐水平下降到177.0 mumol/l,肾小球滤过率增加到30 ml/min/1.73 m2,这与CKD 3b期相对应(肾小球滤过率明显下降)。结论。尽管患者年龄大,有许多合并症,每一种合并症都可能致命,但在门诊及时使用巴西替尼可以阻止疾病的进展过程。版权所有©Eco-Vector, 2023。版权所有。
{"title":"Personalized approach to the management of a patient with COVID-19 with a complicated comorbid background","authors":"S. Chepurnenko, G. Shavkuta, N. M. Bulgakova, A. V. Safonova","doi":"10.33029/2305-3496-2023-12-1-116-122","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-1-116-122","url":null,"abstract":"The aim of the work is to form the principles of a personalized approach to the management of patients with COVID-19 with a complicated comorbid background. Material and methods. The article describes a clinical case of successful recovery of an 87-year-old patient from a new coronavirus infection COVID-19, complicated by pneumonia involving 36% of the lung parenchyma area. Along with age, the situation was aggravated by the comorbid status of the patient: the presence of chronic lymphocytic leukemia, hypertension, mechanical prostheses of the mitral and aortic valves, postinfarction cardiosclerosis, paroxysmal atrial fibrillation, type 2 diabetes mellitus, stage 4 CKD, anemic syndrome, and subclinical hypothyroidism. Results. The C-reactive protein level at admission was 114.46 mg/L. The patient refused hospitalization. Baricitinib 4 mg, favipiravir according to the scheme, vitamin D 2000 units were prescribed for the previously taken therapy. Already after 3 days, C-reactive protein decreased by 4.6 times, and by the 8th day by 15.5 times and amounted to 7.38 mg/ml. The temperature returned to normal on day 2 from the start of baricitinib. In dynamics, a decrease in creatinine level to 177.0 mumol/l was noted, the glomerular filtration rate increased to 30 ml/min/1.73 m2, which corresponded to stage 3b of CKD (a pronounced decrease in glomerular filtration rate). Conclusion. Despite the age of the patient, many comorbidities, each of which could be fatal, the timely use of baricitinib on an outpatient basis made it possible to stop the progressive course of the disease.Copyright © Eco-Vector, 2023. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucosaminylmuramyl dipeptide efficacy in post-COVID-19 patient rehabilitation treatment 葡萄糖氨基muramyl二肽在新冠肺炎患者康复治疗中的疗效观察
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-1-17-25
L. Sizyakina, V. Zakurskaya, S. Guryanova
The COVID-19 pandemic has altered people's lifestyles around the world. Prevention of recurrent episodes of the disease and mitigation of its consequences are especially associated with effective post-COVID-19 rehabilitation in patients. The aim of the study was to evaluate the effects of the drug Likopid (glucosaminylmuramyl dipeptide, GMDP) for post-COVID-19 rehabilitation in patients. Material and methods. Patients who recovered from mild to moderate COVID-19 (n=60, mean age 54+/- 11.7 years) were randomized into the observation group (n=30, 15 men and 15 women) who received 2 courses of Licopid (1 mg twice a day) and the comparison group (n=30, 15 men and 15 women). Analysis of the phenotypic and functional characteristics of the innate immune cellular factors was carried out before the start of immunomodulatory therapy, immediately after the end of the course, and also after 6 months observations. In order to assess the quality of life of all patients, we used the SF-36 Health Status Survey and the Hospital Anxiety and Depression Scale questionnaires. Results. During assessing the effect of immunomodulatory therapy on the parameters of innate immunity of patients at the stage of rehabilitation after COVID-19, an increase in the protective cytolytic activity of CD16+ and CD8+Gr+ cells, as well as a persistent increase in TLR2, TLR4 and TLR9 expression was found, which indicates the antigen recognition recovery and presentation at the level of the monocytic link of the immune system. The use of GMDP as an immunomodulatory agent resulted in an 8-fold reduction in the frequency and severity of respiratory infections due to an increase in the total monocyte count. As a result of assessing patients' quality of life against the background of the therapy, a positive dynamic in role functioning was revealed in patients. In the general assessment of their health status, an increase in physical and mental well-being was noted during 6 months of observation. The comparison group showed no improvement in the psychoemotional state. Discussion. The study demonstrated the effectiveness of GMDP immunomodulatory therapy in correcting immunological parameters for post-COVID-19 rehabilitation in patients. The data obtained are consistent with the previously discovered ability of GMDP to restore impaired functions of phagocytic cells and induce the expression of their surface activation markers, which in turn contributes to an adequate response to pathogens. Conclusion. The study revealed that the correction of immunological parameters with the use of GMDP in COVID-19 convalescents contributed not only to a decrease in the frequency and severity of respiratory infections, but also to an improvement in the psycho-emotional state of patients, and a decrease in anxiety and depression.Copyright © Eco-Vector, 2023. All rights reserved.
新冠肺炎疫情改变了世界各国人民的生活方式。预防疾病复发和减轻其后果尤其与患者在covid -19后的有效康复相关。本研究的目的是评估利柯类药物(glucosaminylmuramyl dipeptide, GMDP)对患者covid -19后康复的影响。材料和方法。将轻至中度COVID-19康复患者(n=60,平均年龄54±11.7岁)随机分为观察组(n=30,男15,女15)和对照组(n=30,男15,女15,每日2次,每次1 mg)。在免疫调节治疗开始前、疗程结束后以及观察6个月后对先天免疫细胞因子的表型和功能特征进行分析。为了评估所有患者的生活质量,我们使用SF-36健康状况调查和医院焦虑和抑郁量表问卷。结果。在评估免疫调节治疗对COVID-19后康复期患者先天免疫参数的影响时,发现CD16+和CD8+Gr+细胞的保护性溶细胞活性增加,TLR2、TLR4和TLR9表达持续增加,表明抗原识别在免疫系统单核环节水平恢复和提呈。使用GMDP作为免疫调节剂,由于单核细胞总数的增加,呼吸道感染的频率和严重程度降低了8倍。作为对治疗背景下患者生活质量评估的结果,角色功能的积极动态在患者中被揭示。在对其健康状况的总体评估中,在6个月的观察期间,注意到身心健康状况有所改善。对照组患者的心理情绪状态无明显改善。讨论。本研究证实了GMDP免疫调节治疗在纠正covid -19患者后康复的免疫参数中的有效性。获得的数据与先前发现的GMDP恢复吞噬细胞受损功能和诱导其表面激活标记物表达的能力一致,这反过来有助于对病原体的充分反应。结论。研究发现,在COVID-19恢复期使用GMDP纠正免疫参数不仅有助于降低呼吸道感染的频率和严重程度,而且有助于改善患者的心理情绪状态,减少焦虑和抑郁。版权所有©Eco-Vector, 2023。版权所有。
{"title":"Glucosaminylmuramyl dipeptide efficacy in post-COVID-19 patient rehabilitation treatment","authors":"L. Sizyakina, V. Zakurskaya, S. Guryanova","doi":"10.33029/2305-3496-2023-12-1-17-25","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-1-17-25","url":null,"abstract":"The COVID-19 pandemic has altered people's lifestyles around the world. Prevention of recurrent episodes of the disease and mitigation of its consequences are especially associated with effective post-COVID-19 rehabilitation in patients. The aim of the study was to evaluate the effects of the drug Likopid (glucosaminylmuramyl dipeptide, GMDP) for post-COVID-19 rehabilitation in patients. Material and methods. Patients who recovered from mild to moderate COVID-19 (n=60, mean age 54+/- 11.7 years) were randomized into the observation group (n=30, 15 men and 15 women) who received 2 courses of Licopid (1 mg twice a day) and the comparison group (n=30, 15 men and 15 women). Analysis of the phenotypic and functional characteristics of the innate immune cellular factors was carried out before the start of immunomodulatory therapy, immediately after the end of the course, and also after 6 months observations. In order to assess the quality of life of all patients, we used the SF-36 Health Status Survey and the Hospital Anxiety and Depression Scale questionnaires. Results. During assessing the effect of immunomodulatory therapy on the parameters of innate immunity of patients at the stage of rehabilitation after COVID-19, an increase in the protective cytolytic activity of CD16+ and CD8+Gr+ cells, as well as a persistent increase in TLR2, TLR4 and TLR9 expression was found, which indicates the antigen recognition recovery and presentation at the level of the monocytic link of the immune system. The use of GMDP as an immunomodulatory agent resulted in an 8-fold reduction in the frequency and severity of respiratory infections due to an increase in the total monocyte count. As a result of assessing patients' quality of life against the background of the therapy, a positive dynamic in role functioning was revealed in patients. In the general assessment of their health status, an increase in physical and mental well-being was noted during 6 months of observation. The comparison group showed no improvement in the psychoemotional state. Discussion. The study demonstrated the effectiveness of GMDP immunomodulatory therapy in correcting immunological parameters for post-COVID-19 rehabilitation in patients. The data obtained are consistent with the previously discovered ability of GMDP to restore impaired functions of phagocytic cells and induce the expression of their surface activation markers, which in turn contributes to an adequate response to pathogens. Conclusion. The study revealed that the correction of immunological parameters with the use of GMDP in COVID-19 convalescents contributed not only to a decrease in the frequency and severity of respiratory infections, but also to an improvement in the psycho-emotional state of patients, and a decrease in anxiety and depression.Copyright © Eco-Vector, 2023. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiogram of Enterococcus spp. associated with post-operative wound infections 肠球菌与术后伤口感染相关的抗生素图
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-1-84-89
Shruthi Shivashankar, N. R. Bhat, B. Dhanashree
{"title":"Antibiogram of Enterococcus spp. associated with post-operative wound infections","authors":"Shruthi Shivashankar, N. R. Bhat, B. Dhanashree","doi":"10.33029/2305-3496-2023-12-1-84-89","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-1-84-89","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Training of specialists in laboratory diagnostics of particularly dangerous infections using ELISA test systems 培训专家使用ELISA检测系统进行特别危险感染的实验室诊断
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-2-100-104
Y. Sizova
{"title":"Training of specialists in laboratory diagnostics of particularly dangerous infections using ELISA test systems","authors":"Y. Sizova","doi":"10.33029/2305-3496-2023-12-2-100-104","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-2-100-104","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lesions of organs and systems in children born from mothers with acute cytomegalovirus infection 急性巨细胞病毒感染母亲所生儿童的器官和系统病变
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-2-57-64
N. Rogozina, V. Vasil’ev, R. Ivanova, G. M. Ushakova, N. Bezverkhaya
{"title":"Lesions of organs and systems in children born from mothers with acute cytomegalovirus infection","authors":"N. Rogozina, V. Vasil’ev, R. Ivanova, G. M. Ushakova, N. Bezverkhaya","doi":"10.33029/2305-3496-2023-12-2-57-64","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-2-57-64","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiologic profile of hepatitis B virus infection among people living with HIV and AIDS 艾滋病毒和艾滋病感染者中乙型肝炎病毒感染的流行病学概况
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-2-65-68
I. Babazarov
{"title":"Epidemiologic profile of hepatitis B virus infection among people living with HIV and AIDS","authors":"I. Babazarov","doi":"10.33029/2305-3496-2023-12-2-65-68","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-2-65-68","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 epidemic process in the Russian Federation: determinants and manifestations 2019冠状病毒病在俄罗斯联邦的流行过程:决定因素和表现
Q4 Social Sciences Pub Date : 2023-01-01 DOI: 10.33029/2305-3496-2023-12-3-8-17
T.A. Platonova, A.A. Golubkova, S.S. Smirnova, V.А. Mishchenko, M.S. Sklyar, E.A. Karbovnichaya, K.V. Varchenko, K.S. Komissarova, A.B. Komissarov, D.A. Lioznov, A.V. Semenov
{"title":"COVID-19 epidemic process in the Russian Federation: determinants and manifestations","authors":"T.A. Platonova, A.A. Golubkova, S.S. Smirnova, V.А. Mishchenko, M.S. Sklyar, E.A. Karbovnichaya, K.V. Varchenko, K.S. Komissarova, A.B. Komissarov, D.A. Lioznov, A.V. Semenov","doi":"10.33029/2305-3496-2023-12-3-8-17","DOIUrl":"https://doi.org/10.33029/2305-3496-2023-12-3-8-17","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136202623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Diseases: News, Opinions, Training
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1